Business Context and Reporting Period
Company: BioLife Solutions, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: BioLife Solutions is a life sciences tools provider specializing in patented biopreservation media products (HypoThermosol, CryoStor, and BloodStor) for cells, tissues, and organs. The company serves regenerative medicine companies, pharmaceutical firms, and biobanks. It transitioned from contract manufacturing to internal GMP-compliant manufacturing in 2009.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenue | $2,081,565 | $1,581,600 |
| Gross Profit | $856,388 | $574,578 |
| Gross Margin | 41.1% | 36.3% |
| Net Loss | $(1,983,630) | $(2,768,352) |
| Operating Loss | $(1,394,196) | $(2,287,365) |
| Cash and Equivalents | $3,211 | $139,151 |
| Working Capital | $474,271 | $535,697 |
| Total Debt (Promissory Notes) | $9,033,127 | $7,888,127 |
| Accumulated Deficit | $(52,194,852) | $(50,211,222) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 32% to $2.08 million, driven by a 33% increase in product sales. This was attributed to new customer acquisition and sales of the BloodStor product line.
- Improved Margins: Gross profit increased 49% to $856,388. The gross margin improved from 36.3% to 41.1% due to higher factory utilization following the transition to in-house manufacturing in 2009.
- Expense Reduction: Total operating expenses decreased 21% to $2.25 million. Notably, "Manufacturing start-up costs" dropped 100% as the one-time costs from the 2009 transition were no longer incurred. R&D and Sales & Marketing expenses also declined by 23% each due to workforce reductions in late 2009.
- Net Loss Improvement: The net loss narrowed by 28% to $1.98 million, primarily due to reduced operating expenses and the elimination of start-up costs, partially offset by higher interest expense.
- Liquidity Decline: Cash and cash equivalents plummeted from $139,151 to $3,211. Net cash used in operating activities was $1.25 million.
Outlook, Risks, and Contingencies
- Going Concern Warning: The company has an accumulated deficit of approximately $52 million and has been unable to generate sufficient income to meet operating needs. The auditors have raised substantial doubt about the company's ability to continue as a going concern.
- Capital Requirements: Management believes current access to credit facilities and customer collections will fund operations through June 30, 2011. Additional capital will be required to reach sustainable positive cash flow. There is no assurance that additional financing will be available or that terms will not be dilutive.
- Debt Structure: The company relies on a Secured Convertible Multi-Draw Term Loan Facility with two related-party investors (Thomas Girschweiler and Walter Villiger). The total principal balance is $9.03 million, with $466,873 remaining available to draw. The repayment date was extended to January 11, 2013.
- Legal Proceedings: The company is involved in multiple lawsuits, including claims by former employees (Kristi Snyder, John G. Baust, John M. Baust) and a lawsuit filed by the company against Cell Preservation Services, Inc. and Coraegis Bioinnovations, Inc. regarding trade secret misappropriation. No accruals have been made for litigation outcomes.
- Customer Concentration: Two customers accounted for 26% of total product sales in 2010. One customer represented 24% of gross accounts receivable.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure additional funding beyond June 2011 given the $3,211 cash balance and $9 million debt load.
- Debt Covenants: Review the terms of the related-party loan facilities to understand conversion rights, interest rates (7%), and potential dilution upon equity financing.
- Legal Exposure: Assess the potential financial impact of ongoing litigation with former executives and competitors, which could result in significant damages or injunctions.
- Revenue Sustainability: Evaluate the dependency on the top two customers (26% of sales) and the progress of customers' clinical trials, which drive demand for biopreservation media.
- Stock Dilution: Note the significant number of outstanding options (14.5 million) and warrants (4.2 million) which could dilute existing shareholders in future financing rounds.